STOCK TITAN

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 9:50 AM ET.

The webcast of the presentation will be accessible here and through the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.”

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact
Evoke Canale
Katherine Smith
Katherine.smith@evokegroup.com

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

Source: Unity Biotechnology, Inc


Unity Biotechnology Inc

NASDAQ:UBX

UBX Rankings

UBX Latest News

UBX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Health Technology, Biotechnology
US
Brisbane

About UBX

unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.